12 news items
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
12 Jun 24
patients with advanced refractory solid tumors. Dr. Song's presentation explored the potential benefits of eliminating
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
3 Jun 24
SNK02 to treat patients with advanced refractory solid tumors. Furthermore, Dr. Song will explore the potential benefits of eliminating pre-treatment
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGN
23 May 24
and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability
Why NKGen Biotech Stock Is Moving Higher Monday
NKGN
20 May 24
insights into the potential benefits and risks of SNK01 in moderate Alzheimer’s Disease, helping clinical researchers to provide validation
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease
NKGN
20 May 24
, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug
y26 jhbt1hc
NKGN
16 May 24
; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute
q3st3fzmaq2fbp79i1wtjt6tu1jr8qj
NKGN
29 Apr 24
the encouraging outcomes regarding the reduction in neuroinflammation observed in our Phase 1 Alzheimer's trials, we are optimistic about the potential benefits
4zutooji600fqjn1l8zus30b8
NKGN
25 Apr 24
benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute
1m8 h6quv6ymho6dsp817f1u6gdvff7
NKGN
24 Apr 24
and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's
u75k99upbn4q4tnqirxsflv4nu12 4ga4h15lyw0
NKGN
11 Apr 24
; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain
sxf1hikmuai5291d5z5p0g0emcs1dom7pasgcee7esl9vioe4o mgt9i
NKGN
25 Mar 24
one year in which we expect to show an even greater clinical benefit. We are excited to continue our research with the goal of offering our NK cell
q0c5x246g q92beqh
NKGN
25 Mar 24
, and prolonged dosing regimen for over one year in which we expect to show an even greater clinical benefit. We are excited to continue our research
- Prev
- 1
- Next